Clearmind Medicine (CMND) announced the filing of a patent application with the Intellectual Property Department in Hong Kong, for a combination therapy designed to treat major depressive disorder. This treatment blends Clearmind’s proprietary 5-methoxy-2-aminoindane with Palmitoylethanolamide, sourced via its partnership with NeuroThera Labs, a subsidiary of SciSparc (SPRC).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: Clearmind advances recruitment for CMND-100 trial’s third cohort
- SciSparc’s Neurothera Labs announces publication of international patent
- Clearmind advances recruitment for CMND-100 trial’s third cohort
- Clearmind Medicine announces publication of patent for weight loss therapy
- Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results